
    
      The study follows an open-label, randomized, 12-week, prospective, interventional
      postauthorization design for the treatment of OAB in approximately 249 Chinese participants.
      Each participant will take part in one 12-week treatment period. Treatments will be
      administered once daily orally after a meal during a 12-week, open-label treatment period.
      Study visits will take place at weeks 4, 8 and 12. For 25 mg mirabegron group, a dose
      escalation to 50 mg is permitted on visit 3 and visit 4 at investigators' discretion.
      Approximately 10 study sites across China are planned.
    
  